A novel kinase inhibitor of FADD phosphorylation chemosensitizes through the inhibition of NF-κB

Molecular Cancer Therapeutics

Volumn 10, Issue 10, 2011, Pages 1807-1817

  Schinske, Katrina A ^a   Nyati, Shyam ^a   Khan, Amjad P ^a   Williams, Terence M ^a   Johnson, Timothy D ^a   Ross, Brian D ^a,b   Tomás, Ricardo Pérez ^c   Rehemtulla, Alnawaz ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CASEIN KINASE IALPHA; CISPLATIN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERIN; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN INHIBITOR;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER THERAPY; CELL ASSAY; CHEMOSENSITIZATION; CONTROLLED STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR CELL;

ALKALOIDS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; HUMANS; JURKAT CELLS; MALE; MICE; MICE, NUDE; NF-KAPPA B; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRROLES; RANDOM ALLOCATION; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80053954562     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0362     Document Type: Article

References (36)

1. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995;81:505-12.
2. Zhang J, Winoto A. A mouse Fas-associated protein with homology to the human Mort1/FADD protein is essential for Fas-induced apoptosis. Mol Cell Biol 1996;16:2756-63.
3. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1-and TNF receptor-induced cell death. Cell 1996;85:803-15.
4. Alappat EC, Feig C, Boyerinas B, Volkland J, Samuels M, Murmann AE, et al. Phosphorylation of FADD at serine 194 by CKIalpha regulates its nonapoptotic activities. Mol Cell 2005;19:321-32. (Pubitemid 41074888)
5. Elrod HA, Sun SY. Modulation of death receptors by cancer therapeutic agents. Cancer Biol Ther 2008;7:163-73. (Pubitemid 351590418)
6. Tourneur L, Chiocchia G. FADD: a regulator of life and death. Trends Immunol 2010;31:260-9.
7. Kabra NH, Kang C, Hsing LC, Zhang J, Winoto A. T cell-specific FADD-deficient mice: FADD is required for early T cell development. Proc Natl Acad Sci U S A 2001;98:6307-12. (Pubitemid 32488235)
8. Imtiyaz HZ, Zhou X, Zhang H, Chen D, Hu T, Zhang J. The death domain of FADD is essential for embryogenesis, lymphocyte development, and proliferation. J Biol Chem 2009;284:9917-26.
9. Zhang J, Kabra NH, Cado D, Kang C, Winoto A. FADD-deficient T cells exhibit a disaccord in regulation of the cell cycle machinery. J Biol Chem 2001;276:29815-8.
10. Hua ZC, Sohn SJ, Kang C, Cado D, Winoto A. A function of Fas-associated death domain protein in cell cycle progression localized to a single amino acid at its C-terminal region. Immunity 2003;18:513-21. (Pubitemid 36513633)
11. Tourneur L, Buzyn A, Chiocchia G. FADD adaptor in cancer. Med Immunol 2005;4:1.
12. Werner MH, Wu C, Walsh CM. Emerging roles for the death adaptor FADD in death receptor avidity and cell cycle regulation. Cell Cycle 2006;5:2332-8. (Pubitemid 44785841)
13. Chen G, Bhojani MS, Heaford AC, Chang DC, Laxman B, Thomas DG, et al. Phosphorylated FADD induces NF-kappaB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proc Natl Acad Sci U S A 2005;102:12507-12. (Pubitemid 41266389)
14. Gibcus JH, Menkema L, Mastik MF, Hermsen MA, de Bock GH, van Velthuysen ML, et al. Amplicon mapping and expression profiling identify the Fas-associated death domain gene as a new driver in the 11q13.3 amplicon in laryngeal/pharyngeal cancer. Clin Cancer Res 2007;13:6257-66. (Pubitemid 350075013)
15. Hu WH, Johnson H, Shu HB. Activation of NF-kappaB by FADD, Casper, and caspase-8. J Biol Chem 2000;275:10838-44. (Pubitemid 30212715)
16. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10. (Pubitemid 37328783)
17. Rochat-Steiner V, Becker K, Micheau O, Schneider P, Burns K, Tschopp J. FIST/HIPK3: a Fas/FADD-interacting serine/threonine kinase that induces FADD phosphorylation and inhibits fas-mediated Jun NH(2)-terminal kinase activation. J Exp Med 2000;192: 1165-74.
18. D'Alessio R, Bargiotti A, Carlini O, Colotta F, Ferrari M, Gnocchi P, et al. Synthesis and immunosuppressive activity of novel prodigiosin derivatives. J Med Chem 2000 Jun 29;43(13):2557-65. (Pubitemid 30437138)
19. Khan AP, Schinske KA, Nyati S, Bhojani MS, Ross BD, Rehemtulla A. High-throughput molecular imaging for the identification of FADD kinase inhibitors. J Biomol Screen 2010;15:1063-70.
20. Nyati S, Ranga R, Ross BD, Rehemtulla A, Bhojani MS. Molecular imaging of glycogen synthase kinase-3beta and casein kinase-1alpha kinases. Anal Biochem 2010;405:246-54.
21. Nasuhara Y, Adcock IM, Catley M, Barnes PJ, Newton R. Differential IkappaB kinase activation and IkappaBalpha degradation by interleukin- 1beta and tumor necrosis factor-alpha in human U937 monocytic cells. Evidence for additional regulatory steps in kappaB-dependent transcription. J Biol Chem 1999;274:19965-72. (Pubitemid 29327783)
22. Monks NR, Biswas DK, Pardee AB. Blocking anti-apoptosis as a strategy for cancer chemotherapy: NF-kappaB as a target. J Cell Biochem 2004;92:646-50. (Pubitemid 44264255)
23. Wajant H, Haas E, Schwenzer R, Muhlenbeck F, Kreuz S, Schubert G, et al. Inhibition of death receptor-mediated gene induction by a cycloheximide- sensitive factor occurs at the level of or upstream of Fas-associated death domain protein (FADD). J Biol Chem 2000;275: 24357-66. (Pubitemid 30626525)
24. Bhojani MS, Chen G, Ross BD, Beer DG, Rehemtulla A. Nuclear localized phosphorylated FADD induces cell proliferation and is associated with aggressive lung cancer. Cell Cycle 2005;4:1478-81.
25. Perez-Tomas R, Vinas M. New insights on the antitumoral properties of prodiginines. Curr Med Chem 2010;17:2222-31.
26. Montaner B, Perez-Tomas R. The prodigiosins: a new family of anticancer drugs. Curr Cancer Drug Targets 2003;3:57-65. (Pubitemid 36119421)
27. Knippschild U, Wolff S, Giamas G, Brockschmidt C, Wittau M, Wurl PU, et al. The role of the casein kinase 1 (CK1) family in different signaling pathways linked to cancer development. Onkologie 2005; 28:508-14. (Pubitemid 41420848)
28. Knippschild U, Gocht A, Wolff S, Huber N, Lohler J, Stoter M. The casein kinase 1 family: participation in multiple cellular processes in eukaryotes. Cell Signal 2005;17:675-89. (Pubitemid 40250168)
29. Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 2005;6:981-8. (Pubitemid 41486182)
30. Balachandran S, Thomas E, Barber GN. A FADD-dependent innate immune mechanism in mammalian cells. Nature 2004;432:401-5. (Pubitemid 39551675)
31. Michallet MC, Meylan E, Ermolaeva MA, Vazquez J, Rebsamen M, Curran J, et al. TRADD protein is an essential component of the RIG-like helicase antiviral pathway. Immunity 2008;28:651-61.
32. Ermolaeva MA, Michallet MC, Papadopoulou N, Utermohlen O, Kranidioti K, Kollias G, et al. Function of TRADD in tumor necrosis factor receptor 1 signaling and in TRIF-dependent inflammatory responses. Nat Immunol 2008;9:1037-46.
33. Hsu H, Shu HB, Pan MG, Goeddel DV. TRADD-TRAF2 and TRADDFADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996;84:299-308. (Pubitemid 26042835)
34. Scaffidi C, Volkland J, Blomberg I, Hoffmann I, Krammer PH, Peter ME. Phosphorylation of FADD/MORT1 at serine 194 and association with a 70-kDa cell cycle-regulated protein kinase. J Immunol 2000; 164:1236-42. (Pubitemid 30067235)
35. Yamamoto C, Takemoto H, Kuno K, Yamamoto D, Tsubura A, Kamata K, et al. Cycloprodigiosin hydrochloride, a new H(+)/Cl(-) symporter, induces apoptosis in human and rat hepatocellular cancer cell lines in vitro and inhibits the growth of hepatocellular carcinoma xenografts in nude mice. Hepatology 1999;30:894-902. (Pubitemid 29458277)
36. Zhang J, Shen Y, Liu J, Wei D. Antimetastatic effect of prodigiosin through inhibition of tumor invasion. Biochem Pharmacol 2005;69: 407-14. (Pubitemid 40094501)